Articles from Dewpoint Therapeutics

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Dewpoint Therapeutics, the leader in condensate biology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to DPTX3186, its first-in-class condensate modulator for the treatment of gastric cancer. The designation follows the recent opening of Dewpoint’s Investigational New Drug (IND) application for DPTX3186, marking the company’s transition to a clinical-stage biotech and the first human study of a condensate-modulating therapeutic.

BOSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Dewpoint Therapeutics today announced the opening of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for DPTX3186, a first-in-class, only-in-class oral condensate modulator (c-mod) designed to selectively disrupt oncogenic Wnt/β-catenin signaling in tumors. Dewpoint plans to begin dosing its first patient before the end of 2025 in a combined Phase 1/2 trial conducted in partnership with leading cancer centers and key opinion leaders in gastric and other Wnt-driven cancers.

BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Dewpoint Therapeutics Inc., a clinical stage biotechnology company that transforms condensate biology into medicine, announced today the publication of an abstract, to be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Annual Meeting, which will take place in Boston, MA, between October 22-26, 2025.

BOSTON, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Dewpoint Therapeutics, the leading biotechnology company in transforming condensate biology into medicine, today announced the closing of its Series D financing to advance DPTX3186, a first-in-class condensate modulator (c-mod), into clinical trials by year-end 2025 and deliver early clinical proof-of-concept by the end of 2026. It will also accelerate development of Dewpoint’s first-in-class c-mod targeting MYC, another historically ‘undruggable’ target, while strengthening ongoing collaborations with Bayer, Novo Nordisk, and Mitsubishi Tanabe Pharma. The financing provides operational runway into early 2027.

BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Dewpoint Therapeutics Inc. – the leading biotechnology company in transforming condensate biology into medicine, announced today the publication of two abstracts accepted for presentation at the American Association of Cancer Research (AACR) Annual Meeting, taking place in Chicago, IL, between April 25-30, 2025.